Amubarvimab, previously known as BRII-196 , represents a significant advancement in biopharmaceutical development, particularly concerning its capacity to block the virus . This monoclonal agent demonstrates https://bookmark-dofollow.com/story28585358/amubarvimab-a-comprehensive-exploration-into-brii-196-s-promise